Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN3018 in R/R AML or R/R HR-MDS
NCT07384715Phase 1Recruiting
- Sponsor
- Genmab
- Start
- Feb 2026
- Primary completion
- Oct 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of GEN3018 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Genmab. Primary endpoints: Dose-limiting Toxicities at 28 days and Adverse Events at 36 months. Started Feb 2026; status: recruiting.
02
Drugs
GEN3018
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07384715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07384715.